Genzyme Corp has announced it will build a new plant in Belgium to produce Lumizyme, its treatment for Pompe disease, a rare genetic disease. Lumizyne is known as Myozyme outside the U.S. The new plant is designed to create redundancy in the company’s manufacturing process, to prevent future drug shortages like the ones created by the temporary shutdown of the company’s Allston plant. The new plant will be the company’s second one in Belgium making Lumizyme. The plant will cost approximately $335 million to build and will create about 150 jobs, bringing the total workforce at the Belgian site to 600. It will include 8,000 liters of production capacity in the form of bioreactors, a complete purification installation, and ample room for additional future capacity expansions. The plant won’t be online until at least late 2014.